Les inhibiteurs de la PCSK9 dans l'arsenal thérapeutique de la gestion du risque cardio-vasculaire
(2018) Louvain médical — Vol. 137, n° 9, p. 497-505 (2018)
Files
2018_Descamps_LM_137_497-505.pdf
Restricted Access - Adobe PDF
- 225.26 KB
Details
- Authors
- Abstract
- (en) [PCSK9 inhibitors in therapeutic arsenal of cardiovascular risk management] In clinical practice, it may at times prove difficult to attain the recommended LDL cholesterol levels due to either high initial levels or low drug tolerance. The 2003 discovery of a new protein named PCSK9 (proprotein convertase subtilisin/kexine Type 9), involved in the metabolism of LDL particles, led to the development of several monoclonal antibodies that neutralize this protein (evolocumab from Amgen, alirocumab from Sanofi/REGENERON, and bocozicumab from Pfizer). When combined with statins and ezetimibe, these agents cause a highly significant reduction in LDL cholesterol levels, associated with very good safety profiles and tolerance, along with significant benefits in terms of cardiovascular prevention. Therefore, they constitute an additional therapeutic strategy to help patients reach their LDL cholesterol targets, especially those with severely elevated cholesterol levels, as observed in familial hypercholesterolemia cases.
- Affiliations
Citations
Descamps, O. (2018). Les inhibiteurs de la PCSK9 dans l’arsenal thérapeutique de la gestion du risque cardio-vasculaire. Louvain médical, 137(9), 497-505. https://hdl.handle.net/2078.5/174013 (Original work published 2018)